Menu
Back to Browse Journals » Pharmacogenomics and Personalized Medicine
Pharmacogenomics and Personalized Medicine
- View all (152)
- Volume 10, 2017 (26)
- Volume 9, 2016 (14)
- Volume 8, 2015 (16)
- Volume 7, 2014 (37)
- Volume 6, 2013 (15)
- Volume 5, 2012 (12)
- Volume 4, 2011 (10)
- Volume 3, 2010 (11)
- Volume 2, 2009 (9)
- Volume 1, 2008 (2)
Journal Articles:
- 152 records -
Do CYP2C19 and ABCB1 gene polymorphisms and low CYP3A4 isoenzyme activity have an impact on stent implantation complications in acute coronary syndrome patients?
Rytkin E, Mirzaev KB, Grishina EA, Smirnov VV, Ryzhikova KA, Sozaeva ZA, Giliarov MI, Andreev DA, Sychev DA
Pharmacogenomics and Personalized Medicine 2017, 10:243-245
Published Date: 18 September 2017
ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine
Piatkov I, Caetano D, Assur Y, Lau SL, Jones T, Boyages SC, McLean M
Pharmacogenomics and Personalized Medicine 2017, 10:235-242
Published Date: 28 August 2017
Hyperbilirubinemia in atazanavir-treated human immunodeficiency virus-infected patients: the impact of the UGT1A1*28 allele
Naidoo A, Naidoo K, Ramsuran V, Reddy M, Padayatchi N
Pharmacogenomics and Personalized Medicine 2017, 10:233-234
Published Date: 23 August 2017
Updating the landscape of direct-to-consumer pharmacogenomic testing
Filipski KK, Murphy JD, Helzlsouer KJ
Pharmacogenomics and Personalized Medicine 2017, 10:229-232
Published Date: 22 August 2017
CYP2D6 phenotypes are associated with adverse outcomes related to opioid medications
St Sauver JL, Olson JE, Roger VL, Nicholson WT, Black III JL, Takahashi PY, Caraballo PJ, Bell EJ, Jacobson DJ, Larson NB, Bielinski SJ
Pharmacogenomics and Personalized Medicine 2017, 10:217-227
Published Date: 24 July 2017
Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder
Zastrozhin MS, Brodyansky VM, Skryabin VY, Grishina EA, Ivashchenko DV, Ryzhikova KA, Savchenko LM, Kibitov AO, Bryun EA, Sychev DA
Pharmacogenomics and Personalized Medicine 2017, 10:209-215
Published Date: 7 July 2017
Hyperbilirubinemia in atazanavir treated HIV-infected patients: the impact of the UGT1A1*28 allele
Panagopoulos P, Maltezos E, Hatzakis A, Paraskevis D
Pharmacogenomics and Personalized Medicine 2017, 10:205-208
Published Date: 20 June 2017
Pharmacogenetics in inflammatory bowel disease: understanding treatment response and personalizing therapeutic strategies
Yamamoto-Furusho JK
Pharmacogenomics and Personalized Medicine 2017, 10:197-204
Published Date: 26 May 2017
Observational study to calculate addictive risk to opioids: a validation study of a predictive algorithm to evaluate opioid use disorder
Brenton A, Richeimer S, Sharma M, Lee C, Kantorovich S, Blanchard J, Meshkin B
Pharmacogenomics and Personalized Medicine 2017, 10:187-195
Published Date: 18 May 2017
CYP2C19*2 status in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis
Laska AJ, Han MJ, Lospinoso JA, Brown PJ, Beachkofsky TM
Pharmacogenomics and Personalized Medicine 2017, 10:183-186
Published Date: 17 May 2017
ABCB1 genetic variants in leukemias: current insights into treatment outcomes
Ankathil R
Pharmacogenomics and Personalized Medicine 2017, 10:169-181
Published Date: 12 May 2017
DNA methylation at the mu-1 opioid receptor gene (OPRM1) promoter predicts preoperative, acute, and chronic postsurgical pain after spine fusion
Chidambaran V, Zhang X, Martin LJ, Ding L, Weirauch MT, Geisler K, Stubbeman BL, Sadhasivam S, Ji H
Pharmacogenomics and Personalized Medicine 2017, 10:157-168
Published Date: 9 May 2017
Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment response
Abaji R, Krajinovic M
Pharmacogenomics and Personalized Medicine 2017, 10:143-156
Published Date: 5 May 2017
ABCG2 polymorphisms in gout: insights into disease susceptibility and treatment approaches
Cleophas MC, Joosten LA, Stamp LK, Dalbeth N, Woodward OM, Merriman TR
Pharmacogenomics and Personalized Medicine 2017, 10:129-142
Published Date: 20 April 2017
Pharmacogenetic testing revisited: 5′nuclease real-time polymerase chain reaction test panels for genotyping CYP2D6 and CYP2C19
Larsen JB, Rasmussen JB
Pharmacogenomics and Personalized Medicine 2017, 10:115-128
Published Date: 18 April 2017
CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome
Mirzaev KB, Zelenskaya EM, Barbarash OL, Ganyukov VI, Apartsin KA, Saraeva NO, Nikolaev KY, Ryzhikova KA, Lifshits GI, Sychev DA
Pharmacogenomics and Personalized Medicine 2017, 10:107-114
Published Date: 12 April 2017
Association of the PPP3CA c.249G>A variant with clinical outcomes of tacrolimus-based therapy in kidney transplant recipients
Salgado PC, Genvigir FDV, Felipe CR, Tedesco-Silva Jr H, Medina-Pestana JO, Doi SQ, Hirata MH, Hirata RDC
Pharmacogenomics and Personalized Medicine 2017, 10:101-106
Published Date: 31 March 2017
Comparison of CYP2C9, CYP2C19, CYP2D6, ABCB1, and SLCO1B1 gene-polymorphism frequency in Russian and Nanai populations
Sychev DA, Shuev GN, Suleymanov SS, Ryzhikova KA, Mirzaev KB, Grishina EA, Snalina NE, Sozaeva ZA, Grabuzdov AM, Matsneva IA
Pharmacogenomics and Personalized Medicine 2017, 10:93-99
Published Date: 31 March 2017
Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals
Trinks J, Caputo M, Hulaniuk ML, Corach D, Flichman D
Pharmacogenomics and Personalized Medicine 2017, 10:79-91
Published Date: 28 March 2017
MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy
Umerez M, Gutierrez-Camino Á, Muñoz-Maldonado C, Martin-Guerrero I, Garcia-Orad A
Pharmacogenomics and Personalized Medicine 2017, 10:69-78
Published Date: 27 March 2017
UGT1A1 polymorphisms in cancer: impact on irinotecan treatment
Takano M, Sugiyama T
Pharmacogenomics and Personalized Medicine 2017, 10:61-68
Published Date: 28 February 2017
Is there evidence that we should screen the general population for Lynch syndrome with genetic testing? A systematic review
Prince AER, Cadigan RJ, Henderson GE, Evans JP, Adams M, Coker-Schwimmer E, Penn DC, Van Riper M, Corbie-Smith G, Jonas DE
Pharmacogenomics and Personalized Medicine 2017, 10:49-60
Published Date: 20 February 2017
Increased risk of hospitalization for ultrarapid metabolizers of cytochrome P450 2D6
Takahashi PY, Ryu E, Pathak J, Jenkins GD, Batzler A, Hathcock MA, Black JL, Olson JE, Cerhan JR, Bielinski SJ
Pharmacogenomics and Personalized Medicine 2017, 10:39-47
Published Date: 14 February 2017
The HLA-A*31:01 allele: influence on carbamazepine treatment
Yip VLM, Pirmohamed M
Pharmacogenomics and Personalized Medicine 2017, 10:29-38
Published Date: 31 January 2017
Prevalence of clinically actionable genotypes and medication exposure of older adults in the community
Daneshi N, Holliday E, Hancock S, Schneider JJ, Scott RJ, Attia J, Milward EA
Pharmacogenomics and Personalized Medicine 2017, 10:17-27
Published Date: 27 January 2017
Diet and lifestyle factors associated with miRNA expression in colorectal tissue
Slattery ML, Herrick JS, Mullany LE, Stevens JR, Wolff RK
Pharmacogenomics and Personalized Medicine 2017, 10:1-16
Published Date: 20 December 2016
CYP2D6 polymorphisms and their influence on risperidone treatment
Puangpetch A, Vanwong N, Nuntamool N, Hongkaew Y, Chamnanphon M, Sukasem C
Pharmacogenomics and Personalized Medicine 2016, 9:131-147
Published Date: 1 December 2016
Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics
Lally J, Gaughran F, Timms P, Curran SR
Pharmacogenomics and Personalized Medicine 2016, 9:117-129
Published Date: 7 November 2016
Pharmacogenetic polymorphism as an independent risk factor for frequent hospitalizations in older adults with polypharmacy: a pilot study
Finkelstein J, Friedman C, Hripcsak G, Cabrera M
Pharmacogenomics and Personalized Medicine 2016, 9:107-116
Published Date: 14 October 2016
Pharmacogenomics of statins: understanding susceptibility to adverse effects
Kitzmiller JP, Mikulik EB, Dauki AM, Mukherjee C, Luzum JA
Pharmacogenomics and Personalized Medicine 2016, 9:97-106
Published Date: 3 October 2016
The correlation between CYP2D6 isoenzyme activity and haloperidol efficacy and safety profile in patients with alcohol addiction during the exacerbation of the addiction
Sychev DA, Zastrozhin MS, Smirnov VV, Grishina EA, Savchenko LM, Bryun EA
Pharmacogenomics and Personalized Medicine 2016, 9:89-95
Published Date: 14 September 2016
Comments on Lucire and Crotty, 2011
Loonen AJM, Verkes RJ
Pharmacogenomics and Personalized Medicine 2016, 9:85-87
Published Date: 18 August 2016
Use of combinatorial pharmacogenomic testing in two cases from community psychiatry
Fields ES, Lorenz RA, Winner JG
Pharmacogenomics and Personalized Medicine 2016, 9:79-84
Published Date: 16 August 2016
Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives
Patel JN
Pharmacogenomics and Personalized Medicine 2016, 9:65-77
Published Date: 12 July 2016
The frequency of SLCO1B1*5 polymorphism genotypes among Russian and Sakha (Yakutia) patients with hypercholesterolemia
Sychev DA, Shuev GN, Chertovskih JV, Maksimova NR, Grachev AV, Syrkova OA
Pharmacogenomics and Personalized Medicine 2016, 9:59-63
Published Date: 25 May 2016
The effect of ABCB1 polymorphisms on the outcome of breast cancer treatment
Tulsyan S, Mittal RD, Mittal B
Pharmacogenomics and Personalized Medicine 2016, 9:47-58
Published Date: 27 April 2016
Potential utility of precision medicine for older adults with polypharmacy: a case series study
Finkelstein J, Friedman C, Hripcsak G, Cabrera M
Pharmacogenomics and Personalized Medicine 2016, 9:31-45
Published Date: 15 April 2016
Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents
Dawed AY, Zhou K, Pearson ER
Pharmacogenomics and Personalized Medicine 2016, 9:17-29
Published Date: 6 April 2016
Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives
Myers MB
Pharmacogenomics and Personalized Medicine 2016, 9:7-16
Published Date: 22 January 2016
Initial assessment of the benefits of implementing pharmacogenetics into the medical management of patients in a long-term care facility
Saldivar JS, Taylor D, Sugarman EA, Cullors A, Garces JA, Oades K, Centeno J
Pharmacogenomics and Personalized Medicine 2016, 9:1-6
Published Date: 19 January 2016
Variations in telomere maintenance and the role of telomerase inhibition in gastrointestinal cancer
Heeg S
Pharmacogenomics and Personalized Medicine 2015, 8:171-180
Published Date: 4 December 2015
The use of pharmacogenetics in clinical practice for the treatment of individuals with HIV infection in Thailand
Bushyakanist A, Puangpetch A, Sukasem C, Kiertiburanakul S
Pharmacogenomics and Personalized Medicine 2015, 8:163-170
Published Date: 5 November 2015
A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study
Damronglerd P, Sukasem C, Thipmontree W, Puangpetch A, Kiertiburanakul S
Pharmacogenomics and Personalized Medicine 2015, 8:155-162
Published Date: 3 October 2015
Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib
El-Osta H, Shackelford R
Pharmacogenomics and Personalized Medicine 2015, 8:145-154
Published Date: 29 September 2015
Once-daily dose regimen of ribavirin is interchangeable with a twice-daily dose regimen: randomized open clinical trial
Balk JM, Haenen GRMM, Koc ÖM, Peters R, Bast A, van der Vijgh WJF, Koek GH
Pharmacogenomics and Personalized Medicine 2015, 8:137-144
Published Date: 12 August 2015
Olaparib in the management of ovarian cancer
Bixel K, Hays JL
Pharmacogenomics and Personalized Medicine 2015, 8:127-135
Published Date: 7 August 2015
Economic evaluations of personalized medicine: existing challenges and current developments
Shabaruddin FH, Fleeman ND, Payne K
Pharmacogenomics and Personalized Medicine 2015, 8:115-126
Published Date: 24 June 2015
The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors
Sychev DA, Denisenko NP, Sizova ZM, Grachev AV, Velikolug KA
Pharmacogenomics and Personalized Medicine 2015, 8:111-114
Published Date: 27 May 2015
The current and future state of companion diagnostics
Agarwal A, Ressler D, Snyder G
Pharmacogenomics and Personalized Medicine 2015, 8:99-110
Published Date: 31 March 2015
Immune cell-based screening assay for response to anticancer agents: applications in pharmacogenomics
Frick A, Fedoriw Y, Richards K, Damania B, Parks B, Suzuki O, Benton CS, Chan E, Thomas RS, Wiltshire T
Pharmacogenomics and Personalized Medicine 2015, 8:81-98
Published Date: 26 February 2015
Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR
Richer AL, Friel JM, Carson VM, Inge LJ, Whitsett TG
Pharmacogenomics and Personalized Medicine 2015, 8:63-79
Published Date: 20 February 2015
Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics
Beitelshees AL, Voora D, Lewis JP
Pharmacogenomics and Personalized Medicine 2015, 8:43-61
Published Date: 9 February 2015
Awareness regarding clinical application of pharmacogenetics among Japanese pharmacists
Obara T, Abe S, Satoh M, Gutiérrez Ubeda SR, Yoshimachi S, Goto T
Pharmacogenomics and Personalized Medicine 2015, 8:35-41
Published Date: 29 January 2015
Targeted treatments for multiple myeloma: specific role of carfilzomib
Sugumar D, Keller J, Vij R
Pharmacogenomics and Personalized Medicine 2015, 8:23-33
Published Date: 20 January 2015
Asthma pharmacogenetics and the development of genetic profiles for personalized medicine
Ortega VE, Meyers DA, Bleecker ER
Pharmacogenomics and Personalized Medicine 2015, 8:9-22
Published Date: 16 January 2015
Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab
Smolej L
Pharmacogenomics and Personalized Medicine 2015, 8:1-7
Published Date: 22 December 2014
Diabetic retinopathy: variations in patient therapeutic outcomes and pharmacogenomics
Agarwal A, Soliman MK, Sepah YJ, Do DV, Nguyen QD
Pharmacogenomics and Personalized Medicine 2014, 7:399-409
Published Date: 12 December 2014
Finally sofosbuvir: an oral anti-HCV drug with wide performance capability
Kayali Z, Schmidt WN
Pharmacogenomics and Personalized Medicine 2014, 7:387-398
Published Date: 8 December 2014
Mycophenolic acid AUC in Thai kidney transplant recipients receiving low dose mycophenolate and its association with UGT2B7 polymorphisms
Pithukpakorn M, Tiwawanwong T, Lalerd Y, Assawamakin A, Premasathian N, Tasanarong A, Thongnoppakhun W, Vongwiwatana A
Pharmacogenomics and Personalized Medicine 2014, 7:379-385
Published Date: 5 December 2014
Patient profiling in diabetes and role of canagliflozin
Amblee A
Pharmacogenomics and Personalized Medicine 2014, 7:367-377
Published Date: 18 November 2014
Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway
Momtaz P, Postow MA
Pharmacogenomics and Personalized Medicine 2014, 7:357-365
Published Date: 15 November 2014
Applications of pharmacogenetics in children with attention-deficit/hyperactivity disorder
Levy F
Pharmacogenomics and Personalized Medicine 2014, 7:349-356
Published Date: 6 November 2014
Clinical utility of pharmacogenomics in the management of hepatitis C
Trinks J, Hulaniuk ML, Redal MA, Flichman D
Pharmacogenomics and Personalized Medicine 2014, 7:339-347
Published Date: 20 October 2014
Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine
Sadeghi S, Olevsky O, Hurvitz SA
Pharmacogenomics and Personalized Medicine 2014, 7:329-338
Published Date: 15 October 2014
Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders
Chang FC, Fung VS
Pharmacogenomics and Personalized Medicine 2014, 7:317-328
Published Date: 13 October 2014
Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition
Audeh MW
Pharmacogenomics and Personalized Medicine 2014, 7:307-316
Published Date: 3 October 2014
Pharmacogenetic information for patients on drug labels
Haga SB, Mills R, Moaddeb J
Pharmacogenomics and Personalized Medicine 2014, 7:297-305
Published Date: 3 October 2014
Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer
Yap TA, Popat S
Pharmacogenomics and Personalized Medicine 2014, 7:285-295
Published Date: 19 September 2014
Developing genomic knowledge bases and databases to support clinical management: current perspectives
Huser V, Sincan M, Cimino JJ
Pharmacogenomics and Personalized Medicine 2014, 7:275-283
Published Date: 9 September 2014
Tailoring therapy for heart failure: the pharmacogenomics of adrenergic receptor signaling
Femminella GD, Barrese V, Ferrara N, Rengo G
Pharmacogenomics and Personalized Medicine 2014, 7:267-273
Published Date: 9 September 2014
Developments in renal pharmacogenomics and applications in chronic kidney disease
Padullés A, Rama I, Llaudó I, Lloberas N
Pharmacogenomics and Personalized Medicine 2014, 7:251-266
Published Date: 28 August 2014
Simeprevir for the treatment of hepatitis C virus infection
Izquierdo L, Helle F, François C, Castelain S, Duverlie G, Brochot E
Pharmacogenomics and Personalized Medicine 2014, 7:241-249
Published Date: 14 August 2014
Implementation and utilization of genetic testing in personalized medicine
Abul-Husn NS, Owusu Obeng A, Sanderson SC, Gottesman O, Scott SA
Pharmacogenomics and Personalized Medicine 2014, 7:227-240
Published Date: 13 August 2014
Analytical strategies for discovery and replication of genetic effects in pharmacogenomic studies
Kohler JR, Guennel T, Marshall SL
Pharmacogenomics and Personalized Medicine 2014, 7:217-225
Published Date: 13 August 2014
Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways
Hosford SR, Miller TW
Pharmacogenomics and Personalized Medicine 2014, 7:203-215
Published Date: 6 August 2014
Dysregulation of the homeobox transcription factor gene HOXB13: role in prostate cancer
Decker B, Ostrander EA
Pharmacogenomics and Personalized Medicine 2014, 7:193-201
Published Date: 5 August 2014
MicroRNA binding site polymorphisms as biomarkers in cancer management and research
Cipollini M, Landi S, Gemignani F
Pharmacogenomics and Personalized Medicine 2014, 7:173-191
Published Date: 23 July 2014
CYP19A1 single nucleotide polymorphism associations with CYP19A1, NFκB1, and IL6 gene expression in human normal colon and normal liver samples
Penney RB, Lundgreen A, Yao-Borengasser A, Edavana VK, Williams S, Dhakal I, Wolff RK, Kadlubar S, Slattery ML
Pharmacogenomics and Personalized Medicine 2014, 7:163-171
Published Date: 14 July 2014
Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties
Johansen Taber KA, Dickinson BD
Pharmacogenomics and Personalized Medicine 2014, 7:145-162
Published Date: 10 July 2014
Targeting metastatic colorectal cancer – present and emerging treatment options
Ciombor KK, Berlin J
Pharmacogenomics and Personalized Medicine 2014, 7:137-144
Published Date: 8 July 2014
Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach
Ceriello A, Gallo M, Candido R, De Micheli A, Esposito K, Gentile S, Medea G
Pharmacogenomics and Personalized Medicine 2014, 7:129-136
Published Date: 19 June 2014
Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders
Saruwatari J, Nakashima H, Tsuchimine S, Nishimura M, Ogusu N, Yasui-Furukori N
Pharmacogenomics and Personalized Medicine 2014, 7:121-127
Published Date: 28 April 2014
Effects of EPHX1 and CYP3A4 polymorphisms on carbamazepine metabolism in epileptic patients
Caruso A, Bellia C, Pivetti A, Agnello L, Bazza F, Scazzone C, Bivona G, Lo Sasso B, Ciaccio M
Pharmacogenomics and Personalized Medicine 2014, 7:117-120
Published Date: 2 April 2014
Targeted treatments in advanced renal cell carcinoma: focus on axitinib
Verzoni E, Grassi P, Testa I, Iacovelli R, Biondani P, Garanzini E, De Braud F, Procopio G
Pharmacogenomics and Personalized Medicine 2014, 7:107-116
Published Date: 27 March 2014
Precision medicine and personalized breast cancer: combination pertuzumab therapy
Reynolds K, Sarangi S, Bardia A, Dizon DS
Pharmacogenomics and Personalized Medicine 2014, 7:95-105
Published Date: 20 March 2014
ALK-driven tumors and targeted therapy: focus on crizotinib
Murga-Zamalloa C, Lim MS
Pharmacogenomics and Personalized Medicine 2014, 7:87-94
Published Date: 20 March 2014
Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
Siddiqi T, Thomas SH, Chen R
Pharmacogenomics and Personalized Medicine 2014, 7:79-85
Published Date: 20 February 2014
Glioblastoma extracellular vesicles: reservoirs of potential biomarkers
Redzic JS, Ung TH, Graner MW
Pharmacogenomics and Personalized Medicine 2014, 7:65-77
Published Date: 13 February 2014
Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics
Noguchi K, Katayama K, Sugimoto Y
Pharmacogenomics and Personalized Medicine 2014, 7:53-64
Published Date: 5 February 2014
Molecular variants and mutations in medulloblastoma
Schroeder K, Gururangan S
Pharmacogenomics and Personalized Medicine 2014, 7:43-51
Published Date: 4 February 2014
Targeted treatment of folate receptor-positive platinum-resistant ovarian cancer and companion diagnostics, with specific focus on vintafolide and etarfolatide
Serpe L, Gallicchio M, Canaparo R, Dosio F
Pharmacogenomics and Personalized Medicine 2014, 7:31-42
Published Date: 29 January 2014
Dabrafenib for treatment of BRAF-mutant melanoma
Kainthla R, Kim KB, Falchook GS
Pharmacogenomics and Personalized Medicine 2014, 7:21-29
Published Date: 31 December 2013
Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients
Tessari A, Palmieri D, Di Cosimo S
Pharmacogenomics and Personalized Medicine 2014, 7:1-19
Published Date: 16 December 2013
Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer
Leamon PC, Lovejoy CD, Nguyen B
Pharmacogenomics and Personalized Medicine 2013, 6:113-125
Published Date: 25 September 2013
Delivering pharmacogenetic testing in a primary care setting
Mills R, Voora D, Peyser B, Haga SB
Pharmacogenomics and Personalized Medicine 2013, 6:105-112
Published Date: 18 September 2013
Lack of correlation between in silico projection of function and quantitative real-time PCR-determined gene expression levels in colon tissue
Penney RB, Lundgreen A, Yao-Borengasser A, Koroth-Edavana V, Williams S, Wolff R, Slattery ML, Kadlubar S
Pharmacogenomics and Personalized Medicine 2013, 6:99-103
Published Date: 9 September 2013
Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen
Sensorn I, Sirachainan E, Chamnanphol M, Pasomsub E, Trachu N, Supavilai P, Sukasem C, Pinthong D
Pharmacogenomics and Personalized Medicine 2013, 6:93-98
Published Date: 26 August 2013
CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors
Sukasem C, Tunthong R, Chamnanphon M, Santon S, Jantararoungtong T, Koomdee N, Prommas S, Puangpetch A, Vathesatogkit P
Pharmacogenomics and Personalized Medicine 2013, 6:85-91
Published Date: 22 August 2013
Role of biomarkers in understanding and treating children with asthma: towards personalized care
Lang JE, Blake KV
Pharmacogenomics and Personalized Medicine 2013, 6:73-84
Published Date: 21 August 2013
ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitro
Skoglund K, Boiso Moreno S, Baytar M, Jönsson JI, Gréen H
Pharmacogenomics and Personalized Medicine 2013, 6:63-72
Published Date: 20 August 2013
Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia
El Rassi F, Khoury HJ
Pharmacogenomics and Personalized Medicine 2013, 6:57-62
Published Date: 5 August 2013
Molecular targeted therapies in metastatic melanoma
Chakraborty R, Wieland CN, Comfere NI
Pharmacogenomics and Personalized Medicine 2013, 6:49-56
Published Date: 7 June 2013
Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen
Chamnanphon M, Pechatanan K, Sirachainan E, Trachu N, Chantratita W, Pasomsub E, Noonpakdee W, Sensorn I, Sukasem C
Pharmacogenomics and Personalized Medicine 2013, 6:37-48
Published Date: 24 May 2013
Non-small-cell lung cancer: molecular targeted therapy and personalized medicine – drug resistance, mechanisms, and strategies
Sechler M, Cizmic AD, Avasarala S, Van Scoyk M, Brzezinski C, Kelley N, Bikkavilli RK, Winn RA
Pharmacogenomics and Personalized Medicine 2013, 6:25-36
Published Date: 4 April 2013
Copy number variation in sulfotransferase isoform 1A1 (SULT1A1) is significantly associated with enzymatic activity in Japanese subjects
Yu X, Kubota T, Dhakal I, Hasegawa S, Williams S, Ozawa S, Kadlubar S
Pharmacogenomics and Personalized Medicine 2013, 6:19-24
Published Date: 6 March 2013
GSTM1 copy number and promoter haplotype as predictors for risk of recurrence and/or second primary tumor in patients with head and neck cancer
Zhang X, Huang M, Wu X, Kadlubar S, Lin J, Yu X, Fan C, Ning B, Kadlubar FF
Pharmacogenomics and Personalized Medicine 2013, 6:9-17
Published Date: 1 March 2013
Importance of pharmacogenetics in the treatment of children with attention deficit hyperactive disorder: a case report
Tan-kam T, Suthisisang C, Pavasuthipaisit C, Limsila P, Puangpetch A, Sukasem C
Pharmacogenomics and Personalized Medicine 2013, 6:3-7
Published Date: 11 January 2013
Pharmacogenomic considerations in opioid analgesia. [Corrigendum]
Vuilleumier PH, Stamer UM, Landau R
Pharmacogenomics and Personalized Medicine 2013, 6:1-2
Published Date: 14 January 2013
CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients
Sirachainan E, Jaruhathai S, Trachu N, Panvichian R, Sirisinha T, Ativitavas T, Ratanatharathorn V, Chamnanphon M, Sukasem C
Pharmacogenomics and Personalized Medicine 2012, 5:149-153
Published Date: 17 October 2012
Drug targets and predictive biomarkers in the management of metastatic melanoma
Thumar J, Giesen E, Kluger HM
Pharmacogenomics and Personalized Medicine 2012, 5:139-148
Published Date: 28 September 2012
Boceprevir and personalized medicine in hepatitis C virus infection
Habersetzer F, Leboeuf C, Doffoël M, Baumert TF
Pharmacogenomics and Personalized Medicine 2012, 5:125-137
Published Date: 26 September 2012
Personalized medicine and treatment approaches in non-small-cell lung carcinoma
Vadakara J, Borghaei H
Pharmacogenomics and Personalized Medicine 2012, 5:113-123
Published Date: 25 September 2012
Mu opioid receptor (OPRM1) as a predictor of treatment outcome in opiate-dependent individuals of Arab descent
AL-Eitan LN, Jaradat SA, Su SY, Tay GK, Hulse GK
Pharmacogenomics and Personalized Medicine 2012, 5:99-111
Published Date: 7 September 2012
Role of pharmacogenomics in the treatment of tuberculosis: a review
Ramachandran G, Swaminathan S
Pharmacogenomics and Personalized Medicine 2012, 5:89-98
Published Date: 13 September 2012
Pharmacogenomic considerations in opioid analgesia
Vuilleumier PH, Stamer UM, Landau R
Pharmacogenomics and Personalized Medicine 2012, 5:73-87
Published Date: 23 August 2012
Individualized immunosuppression in transplant patients: potential role of pharmacogenetics
Abboudi H, MacPhee IA
Pharmacogenomics and Personalized Medicine 2012, 5:63-72
Published Date: 18 June 2012
ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics
Barratt DT, Coller JK, Hallinan R, Byrne A, White JM, Foster DJR, Somogyi AA
Pharmacogenomics and Personalized Medicine 2012, 5:53-62
Published Date: 18 April 2012
The role of genetics in pre-eclampsia and potential pharmacogenomic interventions
Williams PJ, Morgan L
Pharmacogenomics and Personalized Medicine 2012, 5:37-51
Published Date: 20 January 2012
Association of the 5-HTT gene-linked promoter region (5-HTTLPR) polymorphism with psychiatric disorders: review of psychopathology and pharmacotherapy
Kenna GA, Roder-Hanna N, Leggio L, Zywiak WH, Clifford J, Edwards S, Kenna JA, Shoaff J, Swift RM
Pharmacogenomics and Personalized Medicine 2012, 5:19-35
Published Date: 13 January 2012
Individualization of antiretroviral therapy
Pavlos R, Phillips EJ
Pharmacogenomics and Personalized Medicine 2012, 5:1-17
Published Date: 29 December 2011
Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1
Edavana VK, Yu X, Dhakal IB, Williams S, Ning B, Cook IT, Caldwell D, Falany CN, Kadlubar S
Pharmacogenomics and Personalized Medicine 2011, 4:137-145
Published Date: 17 November 2011
Role of cytochrome P450 genotype in the steps toward personalized drug therapy
Cavallari LH, Jeong H, Bress A
Pharmacogenomics and Personalized Medicine 2011, 4:123-136
Published Date: 7 November 2011
Clinical application of high throughput molecular screening techniques for pharmacogenomics
Wiita AP, Schrijver I
Pharmacogenomics and Personalized Medicine 2011, 4:109-121
Published Date: 8 September 2011
Clinical implementation of RNA signatures for pharmacogenomic decision-making
Tang W, Hu Z, Muallem H, Gulley ML
Pharmacogenomics and Personalized Medicine 2011, 4:95-107
Published Date: 8 September 2011
Role of 5-HT2C receptor gene variants in antipsychotic-induced weight gain
Wallace TJM, Zai CC, Brandl EJ, Müller DJ
Pharmacogenomics and Personalized Medicine 2011, 4:83-93
Published Date: 18 August 2011
Antidepressant-induced akathisia-related homicides associated with diminishing mutations in metabolizing genes of the CYP450 family
Lucire Y, Crotty C
Pharmacogenomics and Personalized Medicine 2011, 4:65-81
Published Date: 1 August 2011
ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer
Vaezi A, Feldman CH, Niedernhofer LJ
Pharmacogenomics and Personalized Medicine 2011, 4:47-63
Published Date: 20 July 2011
A genetic approach to the prediction of drug side effects: bleomycin induces concordant phenotypes in mice of the collaborative cross
Gelinas R, Chesler EJ, Vasconcelos D, Miller DR, Yuan Y, Wang K, Galas D
Pharmacogenomics and Personalized Medicine 2011, 4:35-45
Published Date: 4 July 2011
Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy
Bluth MH, Li J
Pharmacogenomics and Personalized Medicine 2011, 4:11-33
Published Date: 1 April 2011
Optimizing response to gefitinib in the treatment of non-small-cell lung cancer
Pietro Carotenuto, Cristin Roma, Anna Maria Rachiglio, et al
Pharmacogenomics and Personalized Medicine 2011, 4:1-9
Published Date: 14 March 2011
The molecular mechanisms and pharmacotherapy of ATP-sensitive potassium channel gene mutations underlying neonatal diabetes
Veronica Lang, Peter E Light
Pharmacogenomics and Personalized Medicine 2010, 3:145-161
Published Date: 24 November 2010
Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management
Sarah Rofaiel, Esther N Muo, Shaker A Mousa
Pharmacogenomics and Personalized Medicine 2010, 3:129-143
Published Date: 17 September 2010
The future role of personalized medicine in the treatment of glioblastoma multiforme
Jing Li, Chunhui Di, Austin K Mattox, et al
Pharmacogenomics and Personalized Medicine 2010, 3:111-127
Published Date: 19 August 2010
Antiplatelet agents and proton pump inhibitors – personalizing treatment
Eugene Lin, Rajiv Padmanabhan, Majaz Moonis
Pharmacogenomics and Personalized Medicine 2010, 3:101-109
Published Date: 28 June 2010
Impact of genetic polymorphisms on clinical response to antithrombotics
Kena J Lanham, Julie H Oestreich, Steven P Dunn, et al
Pharmacogenomics and Personalized Medicine 2010, 3:87-99
Published Date: 18 June 2010
Update and developments in the treatment of glioblastoma multiforme – focus on bevacizumab
Naveed Wagle, Leia Nghiemphu, Albert Lai, et al
Pharmacogenomics and Personalized Medicine 2010, 3:79-85
Published Date: 9 June 2010
DRD4 and DAT1 in ADHD: Functional neurobiology to pharmacogenetics
Darko Turic, James Swanson, Edmund Sonuga-Barke
Pharmacogenomics and Personalized Medicine 2010, 3:61-78
Published Date: 21 May 2010
Ofatumumab: a novel monoclonal anti-CD20 antibody
Thomas S Lin
Pharmacogenomics and Personalized Medicine 2010, 3:51-59
Published Date: 10 May 2010
Determinants to optimize response to clopidogrel in acute coronary syndrome
Betti Giusti, Anna Maria Gori, Rossella Marcucci, et al
Pharmacogenomics and Personalized Medicine 2010, 3:33-50
Published Date: 8 April 2010
Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies
Darren D O’Rielly, Proton Rahman
Pharmacogenomics and Personalized Medicine 2010, 3:15-31
Published Date: 30 March 2010
Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin
Roberto J Carvalho-Filho, Olav Dalgard
Pharmacogenomics and Personalized Medicine 2010, 3:1-13
Published Date: 11 March 2010
The implications of pharmacogenomics in the treatment of HIV-1-infected patients of African descent
Hector Clarke, Shaker A Mousa
Pharmacogenomics and Personalized Medicine 2009, 2:93-99
Published Date: 10 September 2009
Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine
Peter Avery, Shaymaa S Mousa, Shaker A Mousa
Pharmacogenomics and Personalized Medicine 2009, 2:79-91
Published Date: 13 September 2009
Pharmacogenomics in osteoporosis: Steps toward personalized medicine
Robert Greene, Shaymaa S Mousa, Mohamed Ardawi, et al
Pharmacogenomics and Personalized Medicine 2009, 2:69-78
Published Date: 10 September 2009
Pharmacogenomics in cardiovascular disorders: Steps in approaching personalized medicine in cardiovascular medicine
Christopher Barone, Shaymaa S Mousa, Shaker A Mousa
Pharmacogenomics and Personalized Medicine 2009, 2:59-67
Published Date: 8 September 2009
Influence of socioeconomic lifestyle factors and genetic polymorphism on type 2 diabetes occurrences among Tunisian Arab and Berber groups of Djerba Island
Thouraya Baroudi Ouederni, Ahmed Fadiel, Nejla Stambouli, et al
Pharmacogenomics and Personalized Medicine 2009, 2:49-57
Published Date: 21 August 2009
Genomics and proteomics: Applications in autoimmune diseases
Wolfgang Hueber, William H Robinson
Pharmacogenomics and Personalized Medicine 2009, 2:39-48
Published Date: 17 August 2009
Tailoring treatment of nonsmall cell lung cancer by tissue type: role of pemetrexed
Steven F Powell, Arkadiusz Z Dudek
Pharmacogenomics and Personalized Medicine 2009, 2:21-37
Published Date: 24 June 2009
Lack of association between the A118G polymorphism of the mu opioid receptor gene (OPRM1) and opioid dependence: A meta-analysis
Janet K Coller, Julia Beardsley, James Bignold, Yibai Li, Florence Merg, et al
Pharmacogenomics and Personalized Medicine 2009, 2:9-19
Published Date: 20 March 2009
Pharmacogenomic application of the haptoglobin genotype in the treatment of HDL dysfunction
Avery Schwartz, Shany Blum, Rabea Asleh, Mordechai Pollak, Shiri Kalet-Litman, Andrew P Levy
Pharmacogenomics and Personalized Medicine 2009, 2:1-8
Published Date: 27 February 2009
Integrating epigenomics into pharmacogenomic studies
Wei Zhang, R Stephanie Huang, M Eileen Dolan
Pharmacogenomics and Personalized Medicine 2008, 1:7-14
Published Date: 2 November 2008
Association study of a brain-derived neurotrophic factor polymorphism and short-term antidepressant response in major depressive disorders
Eugene Lin, Po See Chen, Lung-Cheng Huang, Sen-Yen Hsu
Pharmacogenomics and Personalized Medicine 2008, 1:1-6
Published Date: 21 October 2008